ApiFix completed a Series B equity financing. The company is pursuing 2019 FDA clearance and subsequent U.S. launch of MID-C for the treatment of scoliosis in young patients.
Minimally Invasive Deformity Correction (MID-C) is a posterior dynamic deformity correction system that supports curve correction while retaining spine flexibility. The removable system acts as an internal brace and employs a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time.
Palm Tree IV, a new U.S.-based investor, led the round with participation from existing shareholders.
ApiFix completed a Series B equity financing. The company is pursuing 2019 FDA clearance and subsequent U.S. launch of MID-C for the treatment of scoliosis in young patients.
Minimally Invasive Deformity Correction (MID-C) is a posterior dynamic deformity correction system that supports curve correction while retaining spine flexibility. The...
ApiFix completed a Series B equity financing. The company is pursuing 2019 FDA clearance and subsequent U.S. launch of MID-C for the treatment of scoliosis in young patients.
Minimally Invasive Deformity Correction (MID-C) is a posterior dynamic deformity correction system that supports curve correction while retaining spine flexibility. The removable system acts as an internal brace and employs a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time.
Palm Tree IV, a new U.S.-based investor, led the round with participation from existing shareholders.
Copy to clipboard 
